Artelo Biosciences (NASDAQ:ARTL) is a biopharmaceutical company focused on developing and commercializing a diverse portfolio of novel therapeutics targeting the endocannabinoid system. The company's operations span across the research and development of innovative treatments designed to address significant unmet medical needs in areas such as cancer, pain, and inflammation. With projects ranging from preclinical to phase trial stages, Artelo is dedicated to pushing the boundaries of science to improve health outcomes. The objective of Artelo is to leverage its expertise in the endocannabinoid system to bring groundbreaking therapies to market, ultimately improving patient care and advancing the field of medicine.